Search results
This Web site may contain general information relating to various medical conditions and their treatment. Such information is provided for informational purposes only and is not meant to be a substitute for advice provided by a doctor or other qualified health care professional.
Conserving natural resources through water recycling and energy efficiency project. At many of our sites and in the communities where we work, Pfizer supports and undertakes environmental projects that restore land, preserve wildlife, and help conserve natural resources.
Connect with Us Investors Careers Media Science Contact Us. Home Our Products Product Listing
This release contains forward-looking information about Pfizer’s efforts to combat COVID-19, the collaboration between BioNTech and Pfizer to develop a potential COVID-19 vaccine, the BNT162 mRNA vaccine program, and modRNA candidate BNT162b2 (including expectations for clinical trials, a proposed amended protocol for its Phase 3 clinical ...
NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced the establishment of the Pfizer Breakthrough Growth Initiative, through which Pfizer will invest up to $500 million in biotechnology companies to help provide funding and access to Pfizer’s scientific expertise to ensure continuity of the biotechnology companies’ most ...
CRESEMBA CAPSULES 100MG: ISAVUCONAZONIUM SULFATE 186.3 MG EQV ISAVUCONAZOLE . CRESEMBA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 200MG: ISAVUCONAZONIUM SULFATE 372.6 MG EQV ISAVUCONAZOLE .
At Pfizer Singapore, we made a unanimous decision to give back the April JSS payout to the Singapore government and decline all future payouts so that the funding can be redirected to help other companies and individuals in need.
DBL POTASSIUM ACETATE | Pfizer Singapore. Home Our Products Product Listing DBL POTASSIUM ACETATE DBL POTASSIUM ACETATE. DBL POTASSIUM ACETATE CONCENTRATED INJECTION 2.45 G/5 ML: POTASSIUM ACETATE (ANHYDROUS) . Our Purpose Our Science. DBL POTASSIUM ACETATE.
NEW YORK-- (BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) announced today further details regarding the proposed spin-off of its Upjohn Business and the subsequent combination of Mylan and the Upjohn Business to form Viatris Inc.
Through its Global Medical Grants program, Pfizer will provide $5 million in funding to support meritorious educational and research proposals that seek to improve the recognition, diagnosis, treatment and overall management of patients with COVID-19.
